Kintara Therapeutics Presents Case Studies of Glioblastoma Patients Treated with VAL-083 at 2023 European Association for Neuro-Oncology Annual Meeting

[ad_1] SAN DIEGO, Sept. 25, 2023 /PRNewswire/ — Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor therapies, today…

Kintara Therapeutics Announces Fiscal 2023 Year Financial Results and Provides Corporate Update

[ad_1] SAN DIEGO, Sept. 18, 2023 /PRNewswire/ — Kintara Therapeutics, Inc. (NASDAQ: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies,…